
TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a review of 11 cohort studies.
The American Journal of Managed Care
over 26 years ago
HEDIS Measurement Moves Outside the Managed Care Box





